<DOC>
	<DOCNO>NCT01847989</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety pharmacokinetics escalate single dos catridecacog ( recombinant factor XIII , rFXIII ) healthy volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetics Recombinant Factor XIII Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Normal platelet count clot parameter Adequate renal hepatic function If female childbearing potential , negative serum pregnancy test within 21 day enrollment negative urine pregnancy test admission clinical research unit If sexually active male sexually active female childbearing potential , agreement use medically accept form contraception time enrollment completion followup study visit Negative drug alcohol screen Known antibody hypersensitivity FXIII Known bleed hematologic disorder Known allergy yeast Receipt blood product within 30 day screen Donation blood within 30 day prior enrollment Any surgical procedure 30 day prior enrollment Previous history autoimmune disorder involve autoantibody , e.g. , systemic lupus erythematosus Receipt treatment experimental agent within 30 day study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>